BIIB Relative Valuation
BIIB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BIIB is overvalued; if below, it's undervalued.
Historical Valuation
Biogen Inc (BIIB) is now in the Fair zone, suggesting that its current forward PE ratio of 14.21 is considered Fairly compared with the five-year average of 14.11. The fair price of Biogen Inc (BIIB) is between 153.70 to 222.90 according to relative valuation methord.
Relative Value
Fair Zone
153.70-222.90
Current Price：180.75
Fair
14.30
PE
1Y
3Y
5Y
Trailing
Forward
10.64
EV/EBITDA
Biogen Inc. (BIIB) has a current EV/EBITDA of 10.64. The 5-year average EV/EBITDA is 10.30. The thresholds are as follows: Strongly Undervalued below 5.51, Undervalued between 5.51 and 7.91, Fairly Valued between 12.70 and 7.91, Overvalued between 12.70 and 15.10, and Strongly Overvalued above 15.10. The current Forward EV/EBITDA of 10.64 falls within the Historic Trend Line -Fairly Valued range.
12.17
EV/EBIT
Biogen Inc. (BIIB) has a current EV/EBIT of 12.17. The 5-year average EV/EBIT is 12.49. The thresholds are as follows: Strongly Undervalued below 7.26, Undervalued between 7.26 and 9.88, Fairly Valued between 15.11 and 9.88, Overvalued between 15.11 and 17.73, and Strongly Overvalued above 17.73. The current Forward EV/EBIT of 12.17 falls within the Historic Trend Line -Fairly Valued range.
2.88
PS
Biogen Inc. (BIIB) has a current PS of 2.88. The 5-year average PS is 3.42. The thresholds are as follows: Strongly Undervalued below 1.80, Undervalued between 1.80 and 2.61, Fairly Valued between 4.23 and 2.61, Overvalued between 4.23 and 5.04, and Strongly Overvalued above 5.04. The current Forward PS of 2.88 falls within the Historic Trend Line -Fairly Valued range.
9.59
P/OCF
Biogen Inc. (BIIB) has a current P/OCF of 9.59. The 5-year average P/OCF is 11.52. The thresholds are as follows: Strongly Undervalued below 6.06, Undervalued between 6.06 and 8.79, Fairly Valued between 14.25 and 8.79, Overvalued between 14.25 and 16.98, and Strongly Overvalued above 16.98. The current Forward P/OCF of 9.59 falls within the Historic Trend Line -Fairly Valued range.
11.98
P/FCF
Biogen Inc. (BIIB) has a current P/FCF of 11.98. The 5-year average P/FCF is 13.25. The thresholds are as follows: Strongly Undervalued below 6.81, Undervalued between 6.81 and 10.03, Fairly Valued between 16.47 and 10.03, Overvalued between 16.47 and 19.69, and Strongly Overvalued above 19.69. The current Forward P/FCF of 11.98 falls within the Historic Trend Line -Fairly Valued range.
Biogen Inc (BIIB) has a current Price-to-Book (P/B) ratio of 1.46. Compared to its 3-year average P/B ratio of 2.03 , the current P/B ratio is approximately -28.36% higher. Relative to its 5-year average P/B ratio of 2.61, the current P/B ratio is about -44.25% higher. Biogen Inc (BIIB) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 6.41%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 7.00% , the current FCF yield is about -100.00% lower.
1.47
P/B
Median3y
2.03
Median5y
2.61
8.69
FCF Yield
Median3y
6.41
Median5y
7.00
Competitors Valuation Multiple
The average P/S ratio for BIIB's competitors is 7.58, providing a benchmark for relative valuation. Biogen Inc Corp (BIIB) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 2.79%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of BIIB increased by 19.00% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 15.76 to 18.40.
The secondary factor is the Revenue Growth, contributed 2.79%to the performance.
Overall, the performance of BIIB in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Biogen Inc (BIIB) currently overvalued or undervalued?
What is Biogen Inc (BIIB) fair value?
How does BIIB's valuation metrics compare to the industry average?
What is the current P/B ratio for Biogen Inc (BIIB) as of Dec 05 2025?
What is the current FCF Yield for Biogen Inc (BIIB) as of Dec 05 2025?
What is the current Forward P/E ratio for Biogen Inc (BIIB) as of Dec 05 2025?